Phased out programme. Switch to Horizon Europe
The concrete goal of access to risk finance under Horizon 2020 is to support and facilitate access to sources of debt and equity financing by innovative companies of all sizes and also by research centers and universities etc.
This support is given through financial intermediaries.
Dear users of the NCP Flanders website, As of today, the NCP Flanders website has a new look aimed at providing a more user-friendly experience. While the content and services available on the website remain unchanged, the fresh new layout is designed to enhance navigation and accessibility. Pages specifically related to one of the programmes we...
Read moreThe short survey that NCP Flanders is conducting to collect feedback on its services and suggestions on how they can be further improved is open for five more days. The NCP Flanders team greatly appreciates it if you could take a few minutes of your time (if you haven’t done so yet) to provide your answers and suggestions via this...
Read moreNCP Flanders is conducting a short survey to collect feedback on its services and suggestions on how they can be further improved. The NCP Flanders team greatly appreciates it if you could take a few minutes of your time (if you haven’t done so yet) to provide your answers and suggestions via this link. The survey will be open for answers for...
Read moreNCP Flanders is conducting a short survey to collect feedback on its services and suggestions on how they can be further improved. The survey is structured along three main chapters: NCP assistance, info sessions, and NCP website & LinkedIn. If the responding person indicates not to know one of these aspects, the survey will automatically...
Read moreDocuments contain additional information related to this programme, and are similar to related links.
Testimonial
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
